Morepen Laboratories (NSE:MOREPENLAB) Other Long-Term Liabilities: ₹609 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:MOREPENLAB Morepen Laboratories Ltd NSE:MOREPENLAB
75 GF Score
Price ₹53.80
GF Value ₹50.04
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Morepen Laboratories Other Long-Term Liabilities?

Morepen Laboratories NSE:MOREPENLAB +2.57% 75 Other Long-Term Liabilities is ₹609 Mil as of Mar. 2026. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 75/100 and a GF Value™ of ₹50.04 (Fairly Valued). The stock has 4 warning signs investors should review.

Morepen Laboratories's other long-term liabilities for the quarter that ended in Mar. 2026 was ₹609 Mil.

Morepen Laboratories's quarterly other long-term liabilities declined from Sep. 2025 (₹490 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹609 Mil).

Morepen Laboratories's annual other long-term liabilities increased from Mar. 2024 (₹406 Mil) to Mar. 2025 (₹512 Mil) and increased from Mar. 2025 (₹512 Mil) to Mar. 2026 (₹609 Mil).

Morepen Laboratories Other Long-Term Liabilities Related Terms

Morepen Laboratories Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Morepen Laboratories's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Morepen Laboratories Other Long-Term Liabilities Chart

Morepen Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.30 359.51 405.70 512.46 608.67

Morepen Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 512.46 0.00 490.12 0.00 608.67
NSE:MOREPENLAB
75GF Score
Morepen Laboratories Ltd NSE:MOREPENLAB
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Morepen Laboratories Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of ₹609 Mil mean?
Morepen Laboratories (NSE:MOREPENLAB) has a Other Long-Term Liabilities of ₹609 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Morepen Laboratories and its competitors.
Is Morepen Laboratories' Other Long-Term Liabilities too high?
Morepen Laboratories' current Other Long-Term Liabilities is ₹609 Mil. Overall, Morepen Laboratories has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' Other Long-Term Liabilities compare to ZTS?
Morepen Laboratories' Other Long-Term Liabilities of ₹609 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Morepen Laboratories and its competitors. Morepen Laboratories's current Other Long-Term Liabilities is ₹609 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹50.04, compared to a current price of ₹53.80 — trading 7.5% above its estimated fair value. The current Other Long-Term Liabilities is ₹609 Mil. Morepen Laboratories' overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current Other Long-Term Liabilities is ₹609 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?

Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued. The current stock price of ₹53.80 is trading 7.5% above its estimated GF Value™ of ₹50.04. GuruFocus considers Morepen Laboratories to be Fairly Valued.

Key valuation signals for NSE:MOREPENLAB:

  • Other Long-Term Liabilities: ₹609 Mil
  • GF Value™: ₹50.04 vs. price of ₹53.80 (7.5% above fair value)
  • GF Score™: 75/100 with 4 warning signs

No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Morepen Laboratories Business Description

Other Exchanges 500288:India
Address Udyog Vihar-III, Sector-20, 2nd Floor, Tower C, DLF Cyber Park, Gurugram, HR, IND, 122016
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
75GF Score

Get the complete analysis for NSE:MOREPENLAB

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹53.80
Price
₹50.04
GF Value